135 related articles for article (PubMed ID: 15767973)
41. FDA approves first drug to prevent HIV infection.
Roehr B
BMJ; 2012 Jul; 345():e4879. PubMed ID: 22807165
[No Abstract] [Full Text] [Related]
42. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.
Achenbach CJ; Scarsi KK; Murphy RL
Adv Ther; 2010 Jan; 27(1):1-16. PubMed ID: 20204580
[TBL] [Abstract][Full Text] [Related]
43. HIV prevention trial in women is abandoned after drugs show no impact on infection rates.
Roehr B
BMJ; 2011 Apr; 342():d2613. PubMed ID: 21508055
[No Abstract] [Full Text] [Related]
44. Recurrent hypersensitivity to Combivir.
Winston A; McLean K
Int J STD AIDS; 2002 Mar; 13(3):213-4. PubMed ID: 11860701
[TBL] [Abstract][Full Text] [Related]
45. The Truvada wars.
Belluz J
BMJ; 2014 Jun; 348():g3811. PubMed ID: 24961949
[No Abstract] [Full Text] [Related]
46. FDA PrEPares to reduce risk of HIV infection with Truvada®.
Breeze S
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):499. PubMed ID: 23272332
[No Abstract] [Full Text] [Related]
47. HIV pre-exposure prophylaxis.
Morin SF; Yamey G; Rutherford GW
BMJ; 2012 Aug; 345():e5412. PubMed ID: 22890030
[No Abstract] [Full Text] [Related]
48. Letter to the editor: Hypersensitivity to lamivudine and emtricitabine.
Loulergue P; Mir O
Curr HIV Res; 2012 Oct; 10(7):620-3. PubMed ID: 22973837
[No Abstract] [Full Text] [Related]
49. Mexico conference considers pre-exposure prophylaxis for AIDS.
Roehr B
BMJ; 2008 Aug; 337():a1278. PubMed ID: 18703652
[No Abstract] [Full Text] [Related]
50. AIDS research. FDA panel recommends anti-HIV drug for prevention.
Cohen J
Science; 2012 May; 336(6083):792. PubMed ID: 22605725
[No Abstract] [Full Text] [Related]
51. Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
Frange P; Blanche S; Chaix ML
J Antimicrob Chemother; 2013 Nov; 68(11):2694-5. PubMed ID: 23743089
[No Abstract] [Full Text] [Related]
52. Warning issued on non-response rates.
AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094
[No Abstract] [Full Text] [Related]
53. More pre-exposure prophylaxis for rising HIV infection?
Barreiro P
AIDS Rev; 2014; 16(2):118-9. PubMed ID: 24984768
[No Abstract] [Full Text] [Related]
54. Another blue pill for sex: Preventing HIV with Truvada PrEP--already at a pharmacy near you.
Vázquez E
Posit Aware; 2011; 23(5):25-7. PubMed ID: 22563594
[No Abstract] [Full Text] [Related]
55. Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.
Ramiro MA; Llibre JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):598-602. PubMed ID: 24139337
[TBL] [Abstract][Full Text] [Related]
56. Uptake of PrEP for HIV slow among MSM.
Kirby T; Thornber-Dunwell M
Lancet; 2014 Feb; 383(9915):399-400. PubMed ID: 24494225
[No Abstract] [Full Text] [Related]
57. Truvada for HIV prophylaxis in heterosexual patients.
DeDea L
JAAPA; 2012 Oct; 25(10):14. PubMed ID: 23115862
[No Abstract] [Full Text] [Related]
58. Second complete once-daily single tablet therapy in development.
AIDS Patient Care STDS; 2009 Aug; 23(8):680. PubMed ID: 19694037
[No Abstract] [Full Text] [Related]
59. Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.
Tilson HH
Am J Prev Med; 2013 Jan; 44(1 Suppl 2):S151-5. PubMed ID: 23253758
[No Abstract] [Full Text] [Related]
60. Reply to Sachdev et al.
Karris MY; Beekmann SE; Mehta SR; Polgreen PM
Clin Infect Dis; 2014 Jun; 58(12):1788. PubMed ID: 24729555
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
